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OBJECTIVE — Amylin interacts with leptin to alter metabolism. We evaluated, for the ﬁrst
time, amylin- and/or leptin-activated signaling pathways in human peripheral tissues (hPTs).
RESEARCH DESIGN AND METHODS — Leptin and amylin signaling studies were
performed in vitro in human primary adipocytes (hPAs) and human peripheral blood mononu-
clear cells (hPBMCs) and ex vivo in human adipose tissue (hAT) from male versus female
subjects, obese versus lean subjects, and subjects with subcutaneous versus omental adipose
tissue.
RESULTS — The long form of leptin receptor was expressed in human tissues and cells
studiedinexvivoandinvitro,respectively.Leptinandamylinaloneandincombinationactivate
signal transducer and activator of transcription 3 (STAT3), AMP-activated protein kinase, Akt,
and extracellular signal-regulated kinase signaling pathways in hAT ex vivo and hPAs and
hPBMCs in vitro; all phosphorylation events were saturable at leptin and amylin concentrations
of50and20ng/ml,respectively.TheeffectsofleptinandamylinonSTAT3phosphorylation
in hPAs and hPBMCs in vitro were totally abolished under endoplasmic reticulum stress and/
or in the presence of a STAT3 inhibitor. Results similar to those in the in vitro studies were
observed in hAT studied ex vivo.
CONCLUSIONS — Leptinandamylinactivateoverlappingintracellularsignalingpathways
in humans and have additive, but not synergistic, effects in signaling pathways studied in hPTs
in vitro and ex vivo.
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L
eptin is an adipocyte-secreted hor-
mone that plays a major role in en-
ergyhomeostasisandweightbalance
(1). Leptin not only activates central ner-
vous system networks that suppress ap-
petite (1) but also acts in the periphery to
alter immune function and metabolism
(2). Leptin administration to leptin-
deﬁcient (ob/ob) mice has been shown to
reduce food intake and body mass and
improve insulin resistance even before
body weight is reduced (3). Moreover,
leptin improves insulin resistance in lep-
tin-deﬁcient lipoatrophic mice and hu-
mans with the metabolic syndrome and
insulin resistance (3). Amylin is a 37-
amino acid peptide hormone that is cose-
creted with insulin from pancreatic
-cells (4). The physiological effects of
amylin receptor agonism include de-
creased food intake (4) and reduction of
postprandial glucagon release in a glu-
cose-dependent manner (5). Moreover, it
has been proposed that treatment with a
combination of amylin and leptin may be
more effective than leptin or amylin alone
for obesity treatment in both animals (2)
and humans (5).
Comprehensive pharmacological
studies demonstrated that concurrent
amylin and leptin infusion synergistically
reduce body weight and adiposity in diet-
induced obesity in rats (6). It has also
been demonstrated that acute amylin in-
fusion ampliﬁes central leptin signaling,
and with sustained treatment amylin and
leptin elicit synergistic weight and fat loss
(6). Amylin-treated rats demonstrate a
trend for a greater number of phosphory-
lated (p)-signal transducer and activator
of transcription (STAT) 3–positive cells
within the arcuate nucleus than vehicle-
treatedcontrols,aneffectsimilartothatof
leptin, whereas rats treated with both
amylin and leptin have signiﬁcantly more
p-STAT3–positive cells than vehicle-,
amylin-, or leptin-treated rats (7). Fur-
thermore, this study also demonstrated
that leptin receptor mRNA was signiﬁ-
cantly increased by amylin/leptin coinfu-
sion both centrally and peripherally, i.e.,
in white adipose tissue and liver (7).
Moreover, it has been shown that periph-
eral leptin injection in rodents increases
STAT3 and mitogen-activated protein ki-
nase (MAPK) phosphorylation in liver
and adipose tissue (8). No previous study
has evaluated leptin and amylin signaling
in human peripheral tissues (hPTs) nor
investigated how amylin interacts with
leptin to alter signaling in hPTs.
We performed ex vivo and in vitro
signaling studies to clarify the role of lep-
tin and amylin in activating signaling
pathwaysinhPTsaswellastheirpotential
interactions. We ﬁrst investigated in vitro
leptinandamylinsignalinginhumanpri-
mary adipocytes (hPAs) and human pe-
ripheral blood mononuclear cells
(hPBMCs),knowncelltargetsofleptinac-
tion. We then performed ex vivo leptin
and amylin signaling studies in human
adipose tissue (hAT) from subjects with
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sue, male versus female subjects, and
obese versus lean subjects.
RESEARCH DESIGN AND
METHODS— We used hAT from
subjects undergoing laparoscopic adjust-
able gastric banding, hernioplasty, lipo-
suction, or abdominoplasty. The study
protocol was approved by the Institu-
tional Review Board at the Beth Israel
Deaconess Medical Center, and subjects
gave written informed consent to partici-
pate. All subjects were otherwise healthy,
had no evidence of immunological or en-
docrine disease based on physical exami-
nation and routine blood tests, and had
no history of recent infection. The sub-
jects’ age, vital signs, and BMI were re-
corded. We collected tissue samples from
obese (six men and six women aged
31–54 years old with BMI 42–44 kg/m
2)
andlean(threemenandfourwomenaged
22–32 years old with BMI 21–23 kg/m
2)
subjects.
Materials
All primary and secondary antibodies
werepurchasedfromSantaCruzBiotech-
nology (Santa Cruz, CA). Leptin human
recombinants were purchased from
ProSpec-Tany TechnoGene (Rehovot, Is-
rael). Amylin human recombinants were
purchasedfromPhoenixPharmaceuticals
(Burlingame,CA).FBSandFCSwerepro-
vided by Gibco Life Technologies. BSA,
-minimal essential medium (-MEM),
RPMI 1640, NaHCO3, HEPES, biotin,
pantothenate, human transferrin, genta-
micin, insulin, cortisol, triiodothyronine,
dithiothreitol (DTT), tunicamycin
(TUN), and ciglitazone were purchased
from Sigma-Aldrich (St. Louis, MO).
Real-time PCR
The long form of leptin receptor (ObRb)
expression was detected with real-time
(RT)-PCR. RNA was extracted with
TRIzol (Invitrogen, Carlsbad, CA), and
ﬁrst-strand cDNA synthesis was per-
formed using SuperScript III (Invitro-
gen), according to the manufacturer’s
protocol. For RT-PCR, 100 ng of cDNA/
25-l reaction was ampliﬁed using a
TaqMan Gene Expression system (Applied
Biosystems, Foster City, CA), speciﬁc
primers and a FAM-tagged probe set (Ap-
plied Biosystems), and the standard real-
time7500protocol(AppliedBiosystems),
with an initial polymerase activation step
at 95°C for 10 min and 40 cycles. This
included a 15-s melting step at 95°C and
a 1-min annealing-elongation step at
60°C.Theanalysisofrelativegeneexpres-
sion was based on Ct values obtained
from RT-PCR (9).
Ex vivo signaling study in hAT
The ex vivo culture was established ac-
cording to the method described by Kim
et al. (8). In brief, 5–7 g of fresh subcuta-
neous and/or omental hAT was placed
into Krebs-Ringer-HEPES buffer (20
mmol/l, pH 7.4) with 2.5% BSA and 200
nmol/ladenosineat37°Cintheoperating
room and immediately taken to the labo-
ratory for further analysis. In the labora-
tory, the tissue samples were minced into
pieces of 1 mm in diameter, and any
nonadipose and nonmuscle tissue was re-
moved by washing with fresh buffer. The
samples were aliquoted and incubated at
37°C either with or without amylin and
leptin.
hPA culture
The hPA culture was established accord-
ingtothemethoddescribedbyRibetetal.
(10). In brief, subcutaneous and omental
hAT samples were obtained from lean
(35–41 years old, BMI 22–25 kg/m
2) and
obese (34–48 years old, BMI 39–50 kg/
m
2) men and women, respectively. The
hAT was then digested with PBS/
collagenase solution (3 mg collagenase/g
tissue and 1 ml PBS/1 mg collagenase) 
3.5%fattyacid–freeBSAandthenﬁltered
using a ﬁlter bottle unit (sterile funnel
withdouble-layeredgauze),andthesolu-
tion was centrifuged at 1200 rpm for 10
min. The pellets were resuspended in
-MEM supplemented with 15 mmol/l
NaHCO3, 15 mmol/l HEPES, 33 mol/l
biotin,17mol/lpantothenate,10mg/ml
human transferrin, 0.05 mg/ml gentami-
cin, and 10% FBS and then were plated
overnight. After conﬂuence, -MEM was
removed, and the cells were washed once
or twice with Hanks’ balanced salt solu-
tion. To induce adipocyte differentiation,
the cells were exposed to differentiation
medium containing 66 nmol/l insulin,
100 nmol/l cortisol, 0.2 nmol/l triiodo-
thyronine, and 1 g/ml ciglitazone. The
medium was changed every 2 days, and
cells were kept in culture for 28 days.
hPBMC culture
hPBMC was isolated by density gradient
sedimentation on Ficoll-Paque (Pharma-
cia, Uppsala, Sweden) as described previ-
ously(11).Thecellswerewashedtwicein
PBS and resuspended in medium appro-
priateforcellculture(RPMI1640supple-
mentedwith25mmol/lHEPES,2mmol/l
L-glutamine, 100 U/ml penicillin, 100
g/ml streptomycin, and 2.5 g/ml am-
photericin B.
Endoplasmic reticulum stress
induction
The induction of endoplasmic reticulum
stress was established according to the
methoddescribedbyHagiwaraetal.(12).
Inbrief,toinduceendoplasmicreticulum
stress, the cells were pretreated with TUN
(3 g/ml) and/or DTT (1 mmol/l) for 5 h
and subsequently treated with leptin
and/or amylin.
Protein extraction
For total cell extracts, collected cells were
suspended in a lysis buffer containing 20
mmol/l Tris-HCl (pH 7.4), 150 mmol/l
NaCl, 5 mmol/l EDTA, 0.1 mmol/l phe-
nylmethylsulfonyl ﬂuoride, 0.05% apro-
tinin,and0.1%Igepalandthenincubated
for 30 min at 4°C. The suspension was
centrifugedfor25minat14,240g,andthe
supernatantwassavedasthetotalextract.
Next,thepelletwasresuspendedinalysis
buffer containing 50 mmol/l HEPES-
NaOH (pH 7.8), 50 mmol/l KCl, 300
mmol/l NaCl, 0.1 mmol/l EDTA, 1
mmol/l DTT, 0.1 mmol/l phenylmethyl-
sulfonyl ﬂuoride, and 10% (v/v) glycerol.
The suspension was mixed for 30 min at
4°C and centrifuged for 15 min at 890g;
the supernatant was saved as the nuclear
extract.
Western blotting
For Western blotting, proteins were
loaded in each lane. After SDS-PAGE,
proteins were blotted onto nitrocellulose
membranes (Schleicher & Schuell,
Keene, NH). The membranes were
blocked for1hi nTris-buffered saline
(TBS) containing 5% nonfat dry milk and
0.1% Tween 20. Incubation with primary
antibodies was performed overnight in
TBS containing 5% nonfat dry milk, and
then incubation was continued with
horseradish peroxidase secondary anti-
bodies for 2 h. After incubation with an-
tibodies, membranes were washed with
TBS containing 0.1% Tween 20. En-
hanced chemiluminescence was used for
detection. Measurement of signal inten-
sity on nitrocellulose membranes after
Western blotting with various antibodies
was performed using ImageJ processing
and analysis software.
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Data were analyzed using one-way
ANOVA followed by a post hoc test for
multiplecomparisons.Analyseswereper-
formed using SPSS (version 11.5; SPSS,
Chicago, IL).
RESULTS
Leptin receptor expression in hAT ex
vivo and in hPAs and hPBMCs in
vitro
ObRb was expressed in human tissues
and cells studied ex vivo and in vitro, re-
spectively (data not shown). We did not
observe any increase in ObRb expression
as a result of leptin, amylin, and/or
leptinamylin administration for 30 min
compared with the control. In addition,
we did not observe any difference in
ObRb expression in subjects with subcu-
taneous versus omental hAT, male versus
female subjects, and obese versus lean
subjects (data not shown) in the limited
number of subjects studied.
Leptin and amylin signaling: dose-
and time-response curves in hAT ex
vivo and in hPAs and hPBMCs in
vitro from obese female subjects
Ex vivo and in vitro leptin and amylin
administration signiﬁcantly induced
phosphorylation of STAT3 by 2.8-fold
higherthancontrolat30mininhAT(Fig.
1A and B) ex vivo and in hPAs (Fig. 1C)
and hPBMCs (Fig. 1D) in vitro. Impor-
tantly, all leptin and amylin signaling
pathways were activated in a dose-
dependent manner, but activations of all
signaling pathways were saturable at a
leptin concentration of 50 ng/ml and
amylin concentration of 20 ng/ml. We
did not observe any difference in STAT3
activation in subjects with subcutaneous
versus omental hAT, obese versus lean
subjects, and male versus female subjects
(data not shown).
Activation of STAT3 signaling by
administration of leptin and amylin
alone or in combination in hAT ex
vivo and in hPAs and hPBMCs in
vitro from obese female subjects
Basedontheaboveresults(Fig.1),wechose
a representative administration time (30
min) and leptin (50 ng/ml) and amylin (20
ng/ml) concentrations. Either leptin or
amylin stimulated phosphorylation of
STAT3 by 2.8-fold in subcutaneous and
omental hAT ex vivo (supplementary Fig.
1A,availableinanonlineappendixathttp://
care.diabetesjournals.org/cgi/content/full/
dc10-0518/DC1), by 2.9-fold in hPAs
in vitro (supplementary Fig. 1B), and by
2.8-fold in hPBMCs (supplementary
Fig. 1C) in vitro. In addition, coadminis-
tration of leptin and amylin activated
STAT3 signaling in hAT ex vivo by 4.7-
fold,inhPAsinvitroby5.1-fold,andin
hPBMCsinvitroby4.9-fold.Moreover,
nuclear translocation of STAT3 was in-
creasedbyleptin,andthiseffectwasmore
enhanced by coadministration of amylin
in hPAs and hPBMCs in vitro (data not
shown). In contrast, increased STAT3
phosphorylation by leptinamylin ad-
ministration was totally abolished by pre-
treatment with AG490, a STAT3
inhibitor, in hPAs (supplementary Fig.
1D) and hPBMCs (supplementary Fig.
1E) in vitro. Importantly, we observed an
additive, but not synergistic, effect of
amylin on leptin-treated tissues and/or
cells. There was no difference in STAT3
activationinexperimentscomparingsub-
jects with subcutaneous versus omental
hAT,obeseversusleansubjects,andmale
versus female subjects (data not shown).
Activation of extracellular signal-
regulated kinase signaling by
administration of leptin and amylin
alone or in combination in hAT ex
vivo and in hPAs and hPBMCs in
vitro from obese female subjects
Extracellular signal-regulated kinase
(ERK) signaling was activated in leptin-
treated (by 2.3-fold) and amylin-
treated (by 2.2-fold) hAT ex vivo, and
thisactivationwasfurtherincreasedinre-
sponse to coadministration of amylin and
leptin by 3.4-fold (supplementary Fig.
2A, available in an online appendix). As
expected, ERK signaling was activated in
leptin- and amylin-treated hPAs in vitro
by 2.9- and 2.8-fold (supplementary
Fig. 2B) and in hPBMCs in vitro by 2.8-
and 2.7-fold, respectively (supplemen-
tary Fig. 2C). In addition, activation of
ERK signaling in response to leptin and
amylin coadministration in hPAs in vitro
was increased by 5.1-fold and in
hPBMCs in vitro by 4.8-fold, but
leptinamylin-activated ERK signaling
was totally blocked by pretreatment with
anERKinhibitor(supplementaryFig.2,B
andC).Wedidnotobserveanydifference
in ERK activation in comparing cells or
tissues from subjects with subcutaneous
versus omental hAT, obese versus lean
subjects, and male versus female subjects
(data not shown).
Activation of Akt and AMPK
signaling by administration of leptin
and amylin alone or in combination
in hAT ex vivo and in hPAs and
hPBMCs in vitro from obese female
subjects
Leptin activated Akt and AMPK signaling
in hAT ex vivo by 1.9- and 3.5-fold
(supplementary Fig. 3A, available in an
online appendix), in hPAs in vitro by
2.6- and 2.8-fold (supplementary
Fig.3B),andinhPBMCsinvitroby3.0-
and 3.2-fold (supplementary Fig. 3C),
respectively. Amylin also activated Akt
and AMPK signaling in hAT ex vivo by
2.0- and 3.6-fold (supplementary
Fig. 3A), in hPAs in vitro by 2.6- and
2.8-fold (supplementary Fig. 3B), and
in hPBMCs in vitro by 3.0- and 3.1-
fold (supplementary Fig. 3C), respec-
tively. Moreover, activation of Akt and
AMPK signaling by leptin and amylin
alone in hAT ex vivo and in hPAs and
hPBMCs in vitro was increased in re-
sponse to leptin and amylin coadminis-
tration. In contrast, activation of Akt and
AMPK signaling in leptinamylin-
stimulated cells was blocked by pretreat-
ment with each inhibitor. We did not
observe any difference in Akt and/or
AMPK activation in cells or tissues from
subjects with subcutaneous versus omen-
tal hAT, obese versus lean subjects, and
male versus female subjects (data not
shown).
Inhibition of STAT3 signaling by
endoplasmic reticulum stress in
hPAs and hPBMCs in vitro from
obese female subjects
Stimulation of the cells with
leptinamylin led to a marked and sig-
niﬁcant increase in phosphorylation of
STAT3 in hPAs by 5.0-fold (supple-
mentary Fig. 4A, available in an online
appendix) and in hPBMCs by 4.8-fold
(supplementary Fig. 4B), but, when chal-
lenged with endoplasmic reticulum stress
inducers, TUN and/or DTT, the
leptinamylin-activated STAT3 phos-
phorylation was totally abolished, sug-
gesting that amylin could not overcome
endoplasmic reticulum stress–induced
inhibition of leptin-activated STAT3 sig-
naling. We did not observe any difference
in endoplasmic reticulum stress–blocked
STAT3 activation in hPAs and hPBMCs
from obese versus lean and male versus
female subjects (data not shown).
CONCLUSIONS — Leptin, the pro-
totype adipocyte-secreted adipocytokine,
Leptin and amylin signaling
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acting primarily in the hypothalamus (1).
It may also act in the periphery to modu-
late immune and metabolic functions (2).
Peripheral leptin administration has been
demonstrated to phosphorylate STAT3
and MAPK in rodent adipose tissue and
liver (8). Similar effects have not yet been
explored in humans. Amylin, a hormone
Figure1—Leptinandamylinsignaling.Dose-andtime-responsecurvesinhATexvivoandinhPAsandhPBMCsinvitrofromobesefemalesubjects.
ExvivoandinvitroleptinandamylinadministrationinhAT(AandB),hPAs(C),andhPBMCs(D)wereperformedasdescribedindetailin RESEARCH
DESIGN AND METHODS. A–D: The tissues and cells were incubated with leptin and/or amylin (50 ng/ml of leptin and 20 ng/ml of amylin for the
time-responsestudyand30minincubationforthedose-responsestudy).Alltissuelysates(wholeproteinextraction)wereexaminedbyWesternblot
with primary p-STAT3 and STAT3 antibodies. The secondary antibody used was horseradish peroxidase-conjugated anti-mouse and anti-goat
antibodies. All ﬁgures showing quantitative analysis include data from at least three independent experiments. All density values for each protein
band of interest are expressed as a fold increase. All data were analyzed using one-way ANOVA followed by post hoc test for multiple comparisons.
Values are means  SD. Means with different letters are signiﬁcantly different, P  0.05.
Moon and Associates
care.diabetesjournals.org DIABETES CARE, VOLUME 34, NUMBER 1, JANUARY 2011 135secreted from the pancreas, functions to
decrease food intake, gastric emptying.
and glucagon secretion (4). Although
amylin has been proposed to amplify lep-
tin signaling in the hypothalamus,
thereby synergistically effecting weight
and fat loss in animal models (6), the mo-
lecular mechanisms underlying these ef-
fects remain to be fully clariﬁed. We have
previouslydemonstratedthatalteringcir-
culating leptin levels in humans does not
alter circulating amylin levels (13).
Whethertheactionofamylincanincrease
leptin signaling in human tissues remains
to be fully elucidated. More speciﬁcally,
there have been no leptin and amylin sig-
naling studies evaluating hPTs, including
hAT and hPBMCs. Hence, we performed
ex vivo and in vitro signaling studies to
investigatetheroleofamylinandleptinin
activating signaling pathways in hPTs as
well as their potential interaction.
STAT3 mediates the expression of a
variety of genes in response to cell stimuli
and thus plays a key role in many cellular
processessuchascellgrowthandapopto-
sis(8).Infact,disruptingtheabilityofthe
leptin receptor to activate the STAT3
pathway in mice leads to severe obesity
and several other neuroendocrine abnor-
malities (14). The STAT3 pathway is the
ﬁrst identiﬁed signaling mechanism
found to be associated with the leptin re-
ceptor (8). Leptin induces phosphoryla-
tion of STAT3 in keratinocytes,
endometrial cancer cells, hypothalamic
cells, murine adipocytes, and mouse adi-
pose tissue (3,8,15,16). Amylin, similar
to leptin, has been shown to increase the
number of p-STAT3 cells in the arcuate
nucleus of rats (7), and this effect was sig-
niﬁcantly greater with coadministration
of leptin and amylin compared with indi-
vidual treatments (7). Based on these re-
sults, we checked for the ﬁrst time
whether leptin signaling interacts with
amylin in humans and whether cotreat-
ment of amylin and leptin could further
increase leptin-stimulated STAT3 signal-
ing in hPT. We observed that leptin and
amylin increased STAT3 signaling in hAT
ex vivo and hPAs and hPBMCs in vitro,
and the effect of these two hormones was
similar in magnitude and peaked around
the same time. Our data in peripheral tis-
sues are consistent with rodent studies
previously demonstrating that amylin-
treated rats tend to have a greater number
of p-STAT3–positive cells than vehicle
controls in hypothalami (7). Although it
is important to study the effects of leptin
and amylin in human hypothalamic or
other central nervous system cells, our
data suggest that amylin-increased
STAT3signalinginleptin-stimulatedhAT
and cells may have important clinical
implications.
ERK, a member of the MAPK family,
is an additional pathway downstream of
the leptin receptor (16). Leptin has been
shown to activate ERK1/2 in a time- and
dose-dependent manner in several cul-
turedmousecellsinvitroaswellasrodent
tissuesinvivo(17).TheERKpathwayhas
been reported to mediate the effects of
leptinonhumanPBMCsinvitroaswellas
rat kidney and rat adipose tissue (8,17).
Based on these previous studies, we fur-
ther investigated whether amylin could
activate ERK signaling in hPTs, because
no relevant data in humans have been
publishedtodate.Weobservedthatamy-
lin increases ERK activation alone and in
leptin-stimulatedhATexvivoaswellasin
hPAs and hPBMCs in vitro. Because ERK
is a signiﬁcant downstream target for the
physiological effects of leptin (15,16), we
suggest that amylin may also have a ben-
eﬁcial effect on human physiology and
pathophysiology.
AMPK is an evolutionarily conserved
serine/threonine protein kinase central to
the regulation of energy balance at both
the cellular and whole-body level (17). In
its classic role as an intracellular meta-
bolic stress-sensing kinase, AMPK
switches on fatty acid oxidation and glu-
cose uptake, while switching off hepatic
gluconeogenesis, and exerts a broader
roleinmetabolismbycontrollingappetite
(17). In fact, AMPK is involved in cellular
energy homeostasis by AMPK phosphor-
ylation and inhibition of acetyl-CoA car-
boxylase and thus stimulates fatty acid
oxidation(17,18).However,whetherlep-
tin can activate AMPK and/or whether
amylin can activate AMPK to induce fatty
acid oxidation in hPTs has not yet been
demonstrated. We checked leptin and
amylin signaling in hPTs in vitro and ex
vivo and observed that leptin and amylin
increase AMPK activation in all cells.
Moreover, we observed that leptin and
amylin administration directly increases
AMPK activation in hAT ex vivo. Because
AMPK is associated with fatty acid oxida-
tion, which plays a key role in the patho-
physiology of insulin resistance (17),
leptin- and amylin-activated AMPK sig-
nalinginhATandotherperipheraltissues
offers further support to the notion that
the use of these hormones, alone or in
combination, could be a viable strategy in
treating obesity and type 2 diabetes.
The Akt signaling pathway is respon-
sible for cellular processes such as cell
growth,proliferation,andglucosemetab-
olism(19).Ithasbeenshownthatobesity
inducesincreasedlevelsofleptin,insulin,
insulin-likegrowthfactor,tumornecrosis
factor-, and interleukin-6 and reduces
adiponectinlevels(19).Thesealteredfac-
tors change Akt signaling activity, which,
in turn, regulates downstream targets,
leading to increased cell survival and cell
growth and promotion of the cell cycle
(19). Based on these previous results, we
further investigated whether leptin
and/or amylin could activate Akt signal-
ing in hPTs in vitro and ex vivo. We ob-
servedthatleptinandamylinaloneandin
combination increase Akt phosphoryla-
tion in hAT ex vivo as well as hPAs and
hPBMCs in vitro suggesting that leptin
and amylin, alone or in combination,
could have beneﬁcial effects on cell
survival.
We observed that amylin activates
Jak2 signaling pathways in hAT ex vivo
and in hPAs and hPBMCs in vitro (data
notshown).BecauseOBRbhasthecapac-
ity to activate Jak2 (20), we suggest that
amylin-mediated intracellular signaling
pathways ex vivo and in vitro might be
activatednotonlythroughcGMP(21)but
also potentially through Jak2 signaling.
This is the ﬁrst report not only on amylin
interacting with Jak2 signaling in human
peripheral tissues but also on amylin sig-
naling in human peripheral tissues. It has
been suggested that amylin may act
through upregulation of the leptin recep-
torandthatthisinducesSTAT3activation
in hypothalami in rodent in vivo (7). We
did not observe any difference in ObRb
expression in human peripheral tissues
treated with leptin, amylin, and
leptinamylin, but the treatment time
was only 30 min. A longer exposure to
amylin and leptin as well as a receptor
knockdown experiment would also be
useful in determining whether amylin
could act through ObRb in human pe-
ripheral tissues. Because it is impossible
toperformthereceptorknockdownstud-
ies in humans, alternative methods such
as ObRb knockdown in vivo rodent or
mouse studies may have to be performed.
In any case, the lack of ObRb upregula-
tion in our studies excludes this potential
mechanism and suggests that most prob-
ably amylin may activate signaling path-
ways downstream of Jak2. This original
observation has to be replicated by other
studies in the future.
Itisgenerallyacceptedthatobesever-
Leptin and amylin signaling
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responsiveness(3).Wealsoexpectedthat
there would be differences between the
obese versus lean group in terms of leptin
responsiveness. Despite minor differ-
encesinthetimingofsignalingactivation,
we did not observe any differences in sev-
eral leptin-activated signaling pathways
inobeseversusleansubjectsinthetissues
studied. There are a number of potential
explanations for this observation. First,
although there are differences between
obese versus lean subjects in response to
leptin accumulation in the medium of
cultured omental and subcutaneous adi-
pose tissue in the early differentiation
stages in vitro (22), leptin and leptin
mRNA levels are not different in obese
versus lean subjects after full differentia-
tion (23). The effect of leptin on lipolysis
is not different between cultured obese
and lean human adipocytes in vitro (24).
These results demonstrate that there are
major quantitative changes in leptin re-
sponsivenessbetweenobeseandleanadi-
pocytes during differentiating stages, but
not differentiated stages, of hAT in vitro.
We have used differentiated adipocytes
herein. Signaling interactions of leptin
and amylin in various differentiation
stages remain to be studied. Second, al-
thoughwestudiedthesignalingpathways
consideredtobeprimarytargetsofleptin,
on the basis of current evidence deriving
mainly from rodent studies, we have not
looked at all signaling pathways poten-
tially mediating the action of leptin in the
periphery. Moreover, there might be
other, totally unknown, pathways acti-
vated by leptin because there have been
no prior studies on leptin signaling in hu-
man tissues. Much more needs to be
learned in the future. Third, it is also pos-
sible that signaling pathways mediating
leptin actions in peripheral tissues (and
resistance thereof) could be totally differ-
ent from those in hypothalami and/or
other central nervous system areas (25).
Because it has been proposed that cen-
trally administered leptin affects insulin
sensitivity and metabolism in peripheral
tissues, it is possible that differences in
central nervous system signaling between
lean and obese subjects are much more
important than leptin-activated signaling
pathways in the periphery. Fourth, leptin
and amylin act not only in adipose tissue
but also in several other metabolically ac-
tive peripheral tissues, including but not
limited to liver and reproductive organs
(26). Because leptin signaling could differ
between lean and obese subjects in these
tissues and because this difference could
havedirectclinicalimplicationsinmetab-
olism, more studies, focusing on tissues
other than the ones studied herein, need
tobeperformed.Finally,itispossiblethat
signalingpathwaysinhumansmaybedif-
ferent from those in animals, which may
be analogous to the different effect of lep-
tin in regulating neuroendocrine re-
sponse to starvation that we have
previously shown in mice (27) versus hu-
mans (28).
Endoplasmic reticulum stress has
recentlybeenshowntoplayaroleinthe
development of leptin resistance in the
hypothalamus of rodents (13), and it
hasbeensuggestedthatendoplasmicre-
ticulum capacity is directly related to
leptin sensitivity (13,29). This ﬁnding
resulted in suggestions that endoplas-
mic reticulum stress reversal could be
usedasastrategytosensitizeobesemice
and by extension, humans, to leptin.
These previous studies have shown that
the reduction in endoplasmic reticulum
function creates endoplasmic reticulum
stress, blocks leptin action, and gener-
ates leptin resistance in mice, suggest-
ing that endoplasmic reticulum stress
inhibits at an upstream step of STAT3
phosphorylation and provides a poten-
tial mechanism in which increased en-
doplasmic reticulum stress antagonizes
STAT3-mediated leptin signaling (29).
However, whether activation of endo-
plasmic reticulum stress interferes with
leptin and/or amylin signaling in hPTs
has not yet been demonstrated. Here,
wereportfortheﬁrsttimethatTUNand
also DTT pretreatment of human cells
completely blocks leptin- and amylin-
stimulated STAT3 activation in hPAs
and hPBMCs in vitro. Our data demon-
strate that amylin does not function as a
leptin sensitizer to bypass endoplasmic
reticulum stress–induced leptin resis-
tance and suggests that increased ER
stressinobesepeoplemayinduceleptin
and also amylin resistance. Because in
vivo leptin and amylin actions may dif-
fer in comparison to in vitro, studies of
in vivo leptin and amylin signaling in
humansareneededtoproveordisprove
this hypothesis. It is currently impossi-
ble to perform human in vivo endoplas-
mic reticulum stress studies, however,
and thus speciﬁc methods for endoplas-
mic reticulum stress induction in hu-
mans need to be developed.
We believe that our data are impor-
tant from the physiological point of view.
This is the very ﬁrst attempt to map the
intracellular signaling pathways down-
stream of leptin and amylin in human tis-
sues.Thisﬁrstreport,iffollowedbyother
similar reports, will eventually allow full
characterization of signaling pathways in
all peripheral tissues in humans as well as
thecomparativeevaluationofhumanver-
sus animal signaling pathways. This new
knowledge in human physiology will
consequentlyleadtotheveryﬁrstattempt
to also study pathophysiology and later
therapeutics in humans. Although we are
initiating this effort with the current
ground-breaking report, much more
needstobedone(additionaltissues,other
signaling pathways, and other physiolog-
ical conditions) in the future. Despite
these limitations, our initial data in hu-
man tissues suggest 1) that leptin toler-
ance (not resistance) exists in the tissues
studied in human and 2) that unlike ex-
periments in rodents showing a synergis-
tic effect of amylin on leptin-modulated
food intake, the effects of amylin and lep-
tin in human peripheral tissues are addi-
tive and not synergistic.
In summary, despite minor differ-
ences in the timing of signaling activation
in the different tissues and cells studied,
we did not observe major differences in
the magnitude of STAT3 activation in re-
sponse to leptin and amylin administra-
tion in hAT ex vivo and in hPAs and
hPBMCs in vitro. In addition, we did not
observe any differences in STAT3, ERK,
and AMPK phosphorylation when we
compared male versus female and obese
versus lean subjects. Importantly, leptin
and amylin signaling pathways were sat-
urableatalevelof50ng/ml(leptin)and
20 ng/ml (amylin), suggesting that no
additional signaling effect can be ob-
served at doses higher than the above
doses. Although leptin and amylin in
combination increased phosphorylation
of the pathways studied herein, we ob-
served not a multiplicative, but rather an
additive, effect of amylin- on leptin-
stimulated hPTs ex vivo and in vitro. The
present study adds to our recent clinical
data demonstrating that leptin adminis-
tration does not alter circulating amylin
levels (13) and provides preclinical evi-
dence that leptin and amylin administra-
tion activate overlapping intracellular
signaling pathways in human peripheral
tissues. These hormones have an additive
effectinhPTs,furthersuggestingthatlep-
tin and amylin may play an additive role
in regulating obesity and type 2 diabetes
in humans.
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